FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949556875> ?p ?o ?g. }

• W2949556875 endingPage "563" @default.
• W2949556875 startingPage "556" @default.
• W2949556875 abstract "The centre of the attraction of this article is inevitably associated with fucoidan polymers in terms of brown seaweed such as Turbinaria conoides. Fucoidan is a sulphated polysaccharide constitutes fucose as a major principle sugar along with other monosugars such as glucuronic acid, xylose and galactose. The core value of fucoidan in terms of various cancer types were substantially exhibited through targeting the key apoptotic molecules and subsequently mitigate the toxicity that are essentially included in the chemotherapeutic agents and radiation. The pragmatic investigation about the anti-cancer effect of fucoidan in a hepatoblastoma-derived (HepG2) cell line was thoroughly analyzed by the typical techniques such as cell viability, colony formation, cell migration, cell cycle progression, genetic damage and apoptosis along with their nuclear morphology and mitochondrial membrane potential. Following the analyzes, the cell viability was precisely evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. And hence, cell cycle arrest and apoptosis was appropriately examined staining with propidium iodide (PI) and annexin V-fluorescein isothiocyante (FITC) by flowcytometer, respectively. Primarily, genetic damage by fucoidan in HepG2 cell line was evaluated by following Trevigen's comet assay kit. In addition, alteration of nuclear content and mitochondrial membrane potential were also detected with Hoechst and mitochondrial membrane potential dye (JC-1: 5,5'6,6'-tetrachloro-1,1'3,3'tetraethylbenzimi-dazolycarbocyanine iodide) by fluorescence microscopy, respectively. The results of the present study showed that cells constituted with fucoidan/quercetin standard at 50, 100 and 200 μg/ml exhibited cell viability about 71, 60 & 40/80, 65 & 45%, respectively. The above recorded effect of fucoidan was a concentration-dependant inhibition on the basis of decline in colony forming and cell migration potential of HepG2 cancer cells. Compared with untreated control, fucoidan consituted cells were significantly (p ≤ 0.05) accumulated proliferative cells in the G0/G1 phase of the cell cycle in a concentration dependent manner. Increasing concentration of fucoidan (50,100 and 200 μg/ml) was remarkably enhanced the DNA damage which reflected through tail moment value of 3.8, 7.1 & 12.8 folds with respect to the untreated control. Fucoidan induced total apoptotic cells were observed ∼20-40% at 50-200 μg/ml concentrations. The apoptotic cell formation effected by change in the nuclear content and mitochondrial membrane potential was confirmed in HepG2 cancer cells under fluorescence microscopy. It was eventually concluded that the fucoidan display promising anti-cancer activity against HepG2 cancer cells by promoting the inhibition of cell proliferation, migration and cell arrest on concentration dependent-manner that was well correlated with genetic damage and apoptosis." @default.
• W2949556875 created "2019-06-27" @default.
• W2949556875 creator A5004543045 @default.
• W2949556875 creator A5059897879 @default.
• W2949556875 creator A5075432000 @default.
• W2949556875 creator A5088415324 @default.
• W2949556875 creator A5090866067 @default.
• W2949556875 date "2019-01-01" @default.
• W2949556875 modified "2023-10-04" @default.
• W2949556875 title "Anticancer effect of fucoidan on cell proliferation, cell cycle progression, genetic damage and apoptotic cell death in HepG2 cancer cells" @default.
• W2949556875 cites W1800944583 @default.
• W2949556875 cites W1842907629 @default.
• W2949556875 cites W1925560176 @default.
• W2949556875 cites W1968009106 @default.
• W2949556875 cites W1976274503 @default.
• W2949556875 cites W1982589054 @default.
• W2949556875 cites W1989722723 @default.
• W2949556875 cites W1996582543 @default.
• W2949556875 cites W2008933923 @default.
• W2949556875 cites W2014297192 @default.
• W2949556875 cites W2014424662 @default.
• W2949556875 cites W2018692723 @default.
• W2949556875 cites W2022145879 @default.
• W2949556875 cites W2024044275 @default.
• W2949556875 cites W2024970765 @default.
• W2949556875 cites W2043792432 @default.
• W2949556875 cites W2047689303 @default.
• W2949556875 cites W2053839409 @default.
• W2949556875 cites W2074733514 @default.
• W2949556875 cites W2101281390 @default.
• W2949556875 cites W2106787323 @default.
• W2949556875 cites W2120967657 @default.
• W2949556875 cites W2132639442 @default.
• W2949556875 cites W2152671209 @default.
• W2949556875 cites W2160176665 @default.
• W2949556875 cites W2161818053 @default.
• W2949556875 cites W2165447484 @default.
• W2949556875 cites W2166810043 @default.
• W2949556875 cites W233278634 @default.
• W2949556875 cites W2335718842 @default.
• W2949556875 cites W2337102724 @default.
• W2949556875 cites W2594265096 @default.
• W2949556875 cites W2741101813 @default.
• W2949556875 cites W2753238571 @default.
• W2949556875 cites W2765435468 @default.
• W2949556875 cites W2770561834 @default.
• W2949556875 cites W2775971403 @default.
• W2949556875 cites W2780468565 @default.
• W2949556875 cites W2783754831 @default.
• W2949556875 cites W2982035180 @default.
• W2949556875 cites W2991131072 @default.
• W2949556875 doi "https://doi.org/10.1016/j.toxrep.2019.06.005" @default.
• W2949556875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6587026" @default.
• W2949556875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31249789" @default.
• W2949556875 hasPublicationYear "2019" @default.
• W2949556875 type Work @default.
• W2949556875 sameAs 2949556875 @default.
• W2949556875 citedByCount "38" @default.
• W2949556875 countsByYear W29495568752019 @default.
• W2949556875 countsByYear W29495568752020 @default.
• W2949556875 countsByYear W29495568752021 @default.
• W2949556875 countsByYear W29495568752022 @default.
• W2949556875 countsByYear W29495568752023 @default.
• W2949556875 crossrefType "journal-article" @default.
• W2949556875 hasAuthorship W2949556875A5004543045 @default.
• W2949556875 hasAuthorship W2949556875A5059897879 @default.
• W2949556875 hasAuthorship W2949556875A5075432000 @default.
• W2949556875 hasAuthorship W2949556875A5088415324 @default.
• W2949556875 hasAuthorship W2949556875A5090866067 @default.
• W2949556875 hasBestOaLocation W29495568751 @default.
• W2949556875 hasConcept C100817775 @default.
• W2949556875 hasConcept C121608353 @default.
• W2949556875 hasConcept C143425029 @default.
• W2949556875 hasConcept C1491633281 @default.
• W2949556875 hasConcept C153911025 @default.
• W2949556875 hasConcept C185592680 @default.
• W2949556875 hasConcept C190283241 @default.
• W2949556875 hasConcept C2775909754 @default.
• W2949556875 hasConcept C2775934118 @default.
• W2949556875 hasConcept C2780358455 @default.
• W2949556875 hasConcept C29537977 @default.
• W2949556875 hasConcept C31573885 @default.
• W2949556875 hasConcept C53227056 @default.
• W2949556875 hasConcept C54355233 @default.
• W2949556875 hasConcept C552990157 @default.
• W2949556875 hasConcept C55493867 @default.
• W2949556875 hasConcept C62112901 @default.
• W2949556875 hasConcept C86803240 @default.
• W2949556875 hasConcept C95444343 @default.
• W2949556875 hasConcept C96232424 @default.
• W2949556875 hasConceptScore W2949556875C100817775 @default.
• W2949556875 hasConceptScore W2949556875C121608353 @default.
• W2949556875 hasConceptScore W2949556875C143425029 @default.
• W2949556875 hasConceptScore W2949556875C1491633281 @default.
• W2949556875 hasConceptScore W2949556875C153911025 @default.
• W2949556875 hasConceptScore W2949556875C185592680 @default.
• W2949556875 hasConceptScore W2949556875C190283241 @default.
• W2949556875 hasConceptScore W2949556875C2775909754 @default.

• next